BIOMAT Database Logo BIOMAT Database Logo

A multicentre randomized controlled trial of recombinant interferon-alpha-2a in the treatment of patients with chronic hepatitis C. 1997

M Komatsu, and T Ono, and K Nakajima, and I Toyoshima, and M Chiba, and O Masamune, and S Ohkubo, and T Yoshida, and H Yagisawa, and K Komatsu, and H Wakamatsu, and N Yamada, and H Watanabe, and T Mukojima, and M Goto
First Department of Internal Medicine, Akita University School of Medicine, Japan.

Sixty-one chronic hepatitis C patients were randomly assigned to receive either 6 x 10(6) or 9 x 10(6) U of recombinant interferon-alpha-2a (IFN alpha-2a) six days a week for the first two weeks of treatment, followed in both cases by 6 x 10(6) U three days a week for the next 22 weeks. In the low dose group, 11 patients showed a complete response maintained for at least six months, 12 responded but then relapsed and nine did not respond; the corresponding figures in the high dose group were 10, 15 and five patients, respectively. The differences between groups are not statistically significant. Thus, this study provides no evidence of therapeutic benefit from increasing the initial dose of IFN alpha-2a. In both treatment groups, complete responders had significantly lower pretreatment viral titres than nonresponders and were significantly more likely to be infected by type 2a versus type 1b virus.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000410 Alanine Transaminase An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. Alanine Aminotransferase,Glutamic-Pyruvic Transaminase,SGPT,Alanine-2-Oxoglutarate Aminotransferase,Glutamic-Alanine Transaminase,Alanine 2 Oxoglutarate Aminotransferase,Aminotransferase, Alanine,Aminotransferase, Alanine-2-Oxoglutarate,Glutamic Alanine Transaminase,Glutamic Pyruvic Transaminase,Transaminase, Alanine,Transaminase, Glutamic-Alanine,Transaminase, Glutamic-Pyruvic
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

M Komatsu, and T Ono, and K Nakajima, and I Toyoshima, and M Chiba, and O Masamune, and S Ohkubo, and T Yoshida, and H Yagisawa, and K Komatsu, and H Wakamatsu, and N Yamada, and H Watanabe, and T Mukojima, and M Goto
Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial. The Hepatitis Interventional Therapy Group.
January 1990, Journal of hepatology,
M Komatsu, and T Ono, and K Nakajima, and I Toyoshima, and M Chiba, and O Masamune, and S Ohkubo, and T Yoshida, and H Yagisawa, and K Komatsu, and H Wakamatsu, and N Yamada, and H Watanabe, and T Mukojima, and M Goto
Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a: results of a randomized controlled clinical trial.
January 1994, Hepatology (Baltimore, Md.),
M Komatsu, and T Ono, and K Nakajima, and I Toyoshima, and M Chiba, and O Masamune, and S Ohkubo, and T Yoshida, and H Yagisawa, and K Komatsu, and H Wakamatsu, and N Yamada, and H Watanabe, and T Mukojima, and M Goto
Long-term titrated recombinant interferon-alpha 2a in chronic hepatitis C: a randomized controlled trial.
January 1995, Journal of viral hepatitis,
M Komatsu, and T Ono, and K Nakajima, and I Toyoshima, and M Chiba, and O Masamune, and S Ohkubo, and T Yoshida, and H Yagisawa, and K Komatsu, and H Wakamatsu, and N Yamada, and H Watanabe, and T Mukojima, and M Goto
A multicentre randomized clinical trial of recombinant alpha-2a interferon therapy in patients with chronic hepatitis B.
April 1993, The Italian journal of gastroenterology,
M Komatsu, and T Ono, and K Nakajima, and I Toyoshima, and M Chiba, and O Masamune, and S Ohkubo, and T Yoshida, and H Yagisawa, and K Komatsu, and H Wakamatsu, and N Yamada, and H Watanabe, and T Mukojima, and M Goto
Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C.
July 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
M Komatsu, and T Ono, and K Nakajima, and I Toyoshima, and M Chiba, and O Masamune, and S Ohkubo, and T Yoshida, and H Yagisawa, and K Komatsu, and H Wakamatsu, and N Yamada, and H Watanabe, and T Mukojima, and M Goto
A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs.
October 1991, Blood,
M Komatsu, and T Ono, and K Nakajima, and I Toyoshima, and M Chiba, and O Masamune, and S Ohkubo, and T Yoshida, and H Yagisawa, and K Komatsu, and H Wakamatsu, and N Yamada, and H Watanabe, and T Mukojima, and M Goto
Recombinant interferon-alpha-2a for treatment of chronic hepatitis C: results of a multicenter randomized controlled dose study.
April 1997, Liver,
M Komatsu, and T Ono, and K Nakajima, and I Toyoshima, and M Chiba, and O Masamune, and S Ohkubo, and T Yoshida, and H Yagisawa, and K Komatsu, and H Wakamatsu, and N Yamada, and H Watanabe, and T Mukojima, and M Goto
A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
May 2005, Journal of viral hepatitis,
M Komatsu, and T Ono, and K Nakajima, and I Toyoshima, and M Chiba, and O Masamune, and S Ohkubo, and T Yoshida, and H Yagisawa, and K Komatsu, and H Wakamatsu, and N Yamada, and H Watanabe, and T Mukojima, and M Goto
Prolonged treatment of children with chronic hepatitis B with recombinant alpha 2a-interferon: a controlled, randomized study.
March 1991, The American journal of gastroenterology,
M Komatsu, and T Ono, and K Nakajima, and I Toyoshima, and M Chiba, and O Masamune, and S Ohkubo, and T Yoshida, and H Yagisawa, and K Komatsu, and H Wakamatsu, and N Yamada, and H Watanabe, and T Mukojima, and M Goto
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.
November 1989, The New England journal of medicine,
Copied contents to your clipboard!